PIPELINE

TatImmune

Phase III-ready for therapeutic use, phase II-ready for preventive use

HerpesVaxTat

Attenuated and replication-defective vaccine candidates based on HSV-1 vectors expressing the Tat protein in vivo have been tested against HSV and TB, and are completing animal toxicology and safety testing for IND submission for Phase I trials